Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
Document Type
- Journal article (12)
- Doctoral Thesis (1)
Keywords
- early intervention (2)
- ALS (1)
- Astrocytes ; Schwann cells ; Interferon-gamma ; Fibroblast growth factor ; Cyclic AMP (1)
- Bavaria (1)
- Bayern (1)
- CBT (1)
- CD117 (1)
- CK5 (1)
- CSIDH (1)
- DNA fingerprinting (1)
Institute
- Institut für Geographie und Geologie (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Frauenklinik und Poliklinik (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Mathematik (1)
- Institut für Psychologie (1)
- Institut für Psychotherapie und Medizinische Psychologie (1)
- Kinderklinik und Poliklinik (1)
Im Freistaat Bayern wird intensiv diskutiert, wie die nach wie vor hohe Freiflächeninanspruchnahme für Siedlungs- und Verkehrszwecke reduziert werden kann. Wissenschaftliche Grundlage für Steuerungsansätze in der Stadt- und Regionalentwicklung sollte ein verbessertes staatliches Flächenmonitoring sein, welches über die amtliche Statistik und deren Hauptindikator "Siedlungs- und Verkehrsfläche" hinaus auch die qualitative Dimension der Flächeninanspruchnahme einbezieht. Dafür stellt dieser Beitrag methodische Erweiterungsansätze für das Flächenmonitoring vor, welche kleinräumige Analysen der Zersiedelung, Freiraumstruktur, Flächenversiegelung und Ökosystemleistungen am Beispiel des Landkreises Rhön-Grabfeld aufzeigen. Diese werden im Kontext der Debatte zu Ursachen und Steuerung der Freiflächeninanspruchnahme sowie zu aktuellen Anforderungen an das Flächenmonitoring diskutiert. Betont wird deren Bedeutung für das Monitoring rechtlicher Vorgaben und politischer Ziele zur nachhaltigen Flächennutzung.
Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [\(^{11}\)C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [\(^{11}\)C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m\(^2\)) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes.
Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.